Tri Locum Partners LP — 13F Holdings & Portfolio
CIK 1826434 · latest 13F-HR filed 2026-08-14
Tri Locum Partners LP manages $813.2M in 13F-reported U.S. long-equity assets across 19 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are JNJ (13.27%), VRTX (12.33%), LLY (11.29%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 5 new positions, exited 3, added to 9, and trimmed 4.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
NEW YORK, NY 10010
$813.2M
Long-equity book
19
Distinct positions
2026-06-30
Filed 2026-08-14
+5 / −3 / ↑9 / ↓4
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- AXSOME THERAPEUTICS INC.$43.2M +411.3%
- VERTEX PHARMACEUTICALS INC$42.5M +73.6%
- ELI LILLY & CO$35.0M +61.5%
- JAZZ PHARMACEUTICALS PLC$23.4M +78.1%
- ARGENX SE$15.5M +67.1%
Top Trims
- INTUITIVE SURGICAL INC-$51.6M -73.0%
- MADRIGAL PHARMACEUTICALS INC-$17.4M -32.2%
- UNITED THERAPEUTICS CORP DEL-$16.2M -38.9%
- TEVA PHARMACEUTICAL INDS LTD-$5.4M -17.7%
New Positions
- ASCENDIS PHARMA A/S$69.0M
- ENLIVEN THERAPEUTICS INC$44.0M
- REVOLUTION MEDICINES INC$28.4M
- CYTOKINETICS INC$16.5M
- BETA BIONICS INC$7.7M
Exited Positions
- THERMO FISHER SCIENTIFIC INC$65.1M
- ASCENDIS PHARMA A/S$58.4M
- NUVALENT INC$31.6M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | JOHNSON & JOHNSON | JNJ | 478160104 | $107.9M | 13.27% | 424,945 | SH |
| 2 | VERTEX PHARMACEUTICALS INC | VRTX | 92532F100 | $100.2M | 12.33% | 201,791 | SH |
| 3 | ELI LILLY & CO | LLY | 532457108 | $91.8M | 11.29% | 76,532 | SH |
| 4 | ASCENDIS PHARMA A/S | ASND | K08588103 | $69.0M | 8.49% | 258,740 | SH |
| 5 | DEXCOM INC | DXCM | 252131107 | $55.3M | 6.80% | 820,479 | SH |
| 6 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $53.7M | 6.60% | 219,308 | SH |
| 7 | JAZZ PHARMACEUTICALS PLC | JAZZ | G50871105 | $53.4M | 6.57% | 221,720 | SH |
| 8 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $44.0M | 5.41% | 866,716 | SH |
| 9 | ARGENX SE | ARGX | 04016X101 | $38.6M | 4.75% | 41,596 | SH |
| 10 | MADRIGAL PHARMACEUTICALS INC | MDGL | 558868105 | $36.7M | 4.51% | 68,273 | SH |
| 11 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $28.4M | 3.50% | 151,822 | SH |
| 12 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $25.5M | 3.13% | 47,026 | SH |
| 13 | TEVA PHARMACEUTICAL INDS LTD | TEVA | 881624209 | $25.3M | 3.11% | 746,835 | SH |
| 14 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $20.7M | 2.54% | 328,340 | SH |
| 15 | INTUITIVE SURGICAL INC | ISRG | 46120E602 | $19.1M | 2.35% | 47,983 | SH |
| 16 | CYTOKINETICS INC | CYTK | 23282W605 | $16.5M | 2.03% | 194,000 | SH |
| 17 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $11.8M | 1.45% | 120,712 | SH |
| 18 | BETA BIONICS INC | BBNX | 08659B102 | $7.7M | 0.95% | 493,344 | SH |
| 19 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $7.7M | 0.94% | 162,996 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $813.2M | 19 | 0001826434-26-000005 |
| 2026-03-31 | 2026-05-18 | $712.5M | 17 | 0001826434-26-000004 |
| 2025-12-31 | 2026-02-17 | $770.1M | 15 | 0001826434-26-000002 |
| 2025-09-30 | 2025-11-14 | $435.1M | 18 | 0001826434-25-000008 |